Inovio Pharmaceuticals (INO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.99, -4.80% vs the prior close of $1.04.
- Volume 2.05M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
INO slides 4.8% to $0.99. Closed at $0.99, -4.80% vs the prior close of $1.04. Day range $0.99–$1.06, opened at $1.06.
INO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — INO slides 4.8% to $0.99
- Closed at $0.99, -4.80% vs the prior close of $1.04. Day range $0.99–$1.06, opened at $1.06.
- Volume was 2.05M shares, 0.6x its 50-day average of 3.70M — lighter than usual.
- Price is -14.9% vs its 50-day average ($1.16) and -23.9% vs its 200-day average ($1.30).
- 52-week range $0.56–$2.72; today's close sits at 20% of that range, 63.6% below the 52-week high.
Oct 15, 2026 — INO jumps 5.1% to $1.04
- Closed at $1.04, +5.05% vs the prior close of $0.99. Day range $0.96–$1.06, opened at $0.96.
- Volume was 1.76M shares, 0.5x its 50-day average of 3.71M — lighter than usual.
- Price is -10.1% vs its 50-day average ($1.16) and -20.3% vs its 200-day average ($1.31).
- 52-week range $0.56–$2.72; today's close sits at 22% of that range, 61.8% below the 52-week high.
Oct 14, 2026 — INO dips 1.0% to $0.99, a 1-month low, 3 down days in a row
- Closed at $0.99, -1.00% vs the prior close of $1.00. Day range $0.96–$1.02, opened at $1.00.
- Volume was 3.00M shares, 0.8x its 50-day average of 3.73M.
- Price is -13.9% vs its 50-day average ($1.15) and -24.4% vs its 200-day average ($1.31).
- 52-week range $0.56–$2.72; today's close sits at 20% of that range, 63.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — INO slides 9.9% to $1.00, a 1-month low on 2.3x normal volume
- Closed at $1.00, -9.91% vs the prior close of $1.11. Day range $0.95–$1.11, opened at $1.11.
- Volume was 8.47M shares, 2.3x its 50-day average of 3.71M — unusually heavy trading.
- Price is -12.5% vs its 50-day average ($1.14) and -24.0% vs its 200-day average ($1.32).
- 52-week range $0.56–$2.72; today's close sits at 20% of that range, 63.2% below the 52-week high.
Oct 12, 2026 — INO slides 3.5% to $1.11
- Closed at $1.11, -3.48% vs the prior close of $1.15. Day range $1.09–$1.18, opened at $1.16.
- Volume was 2.33M shares, 0.6x its 50-day average of 3.92M — lighter than usual.
- Price is -2.4% vs its 50-day average ($1.14) and -16.0% vs its 200-day average ($1.32).
- 52-week range $0.56–$2.72; today's close sits at 25% of that range, 59.2% below the 52-week high.
Oct 9, 2026 — INO jumps 5.5% to $1.15
- Closed at $1.15, +5.50% vs the prior close of $1.09. Day range $1.07–$1.15, opened at $1.10.
- Volume was 2.89M shares, 0.6x its 50-day average of 4.53M.
- Price is +1.9% vs its 50-day average ($1.13) and -13.3% vs its 200-day average ($1.33).
- 52-week range $0.56–$2.72; today's close sits at 27% of that range, 57.7% below the 52-week high.
Oct 8, 2026 — INO slides 6.0% to $1.09, a 1-month low
- Closed at $1.09, -6.03% vs the prior close of $1.16. Day range $1.08–$1.18, opened at $1.17.
- Volume was 3.21M shares, 0.7x its 50-day average of 4.50M.
- Price is -2.6% vs its 50-day average ($1.12) and -18.2% vs its 200-day average ($1.33).
- 52-week range $0.56–$2.72; today's close sits at 25% of that range, 59.9% below the 52-week high.
Oct 7, 2026 — INO rises 2.7% to $1.16
- Closed at $1.16, +2.65% vs the prior close of $1.13. Day range $1.11–$1.19, opened at $1.12.
- Volume was 2.80M shares, 0.6x its 50-day average of 4.47M.
- Price is +3.8% vs its 50-day average ($1.12) and -13.3% vs its 200-day average ($1.34).
- 52-week range $0.56–$2.72; today's close sits at 28% of that range, 57.4% below the 52-week high.
Oct 6, 2026 — INO dips 1.7% to $1.13, 4 down days in a row
- Closed at $1.13, -1.74% vs the prior close of $1.15. Day range $1.12–$1.17, opened at $1.15.
- Volume was 2.01M shares, 0.5x its 50-day average of 4.46M — lighter than usual.
- Price is +1.3% vs its 50-day average ($1.12) and -15.9% vs its 200-day average ($1.34).
- 52-week range $0.56–$2.72; today's close sits at 26% of that range, 58.5% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 5, 2026 — INO dips 0.9% to $1.15, 3 down days in a row
- Closed at $1.15, -0.86% vs the prior close of $1.16. Day range $1.11–$1.21, opened at $1.20.
- Volume was 2.96M shares, 0.7x its 50-day average of 4.48M.
- Price is +3.4% vs its 50-day average ($1.11) and -14.9% vs its 200-day average ($1.35).
- 52-week range $0.56–$2.72; today's close sits at 27% of that range, 57.7% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — INO slides 4.1% to $1.16
- Closed at $1.16, -4.13% vs the prior close of $1.21. Day range $1.16–$1.23, opened at $1.22.
- Volume was 2.91M shares, 0.7x its 50-day average of 4.47M.
- Price is +4.6% vs its 50-day average ($1.11) and -14.6% vs its 200-day average ($1.36).
- 52-week range $0.56–$2.72; today's close sits at 28% of that range, 57.4% below the 52-week high.
INO latest news & SEC filings
Every SEC filing by or about INO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$6.01M (prior year -$23.52M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.07 (prior year -$0.61) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Jul 30, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 10, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Jul 2, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade INO
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: Jul 29, 2026, May 13, 2026, Mar 12, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.73% (largest 9.9%). That is a volatile stock.
- Liquidity: about 2.89M shares (≈$2.86M) trade per day on average.
- 52-week position: $0.99 vs a range of $0.56–$2.72 (20% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 6, 2026; 8-K Aug 12, 2026; 10-Q Aug 12, 2026.
- Share count: 103.40M shares outstanding (Aug 10, 2026), +94.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
INO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.06 | 1.06 | 0.99 | 0.99 | 2.05M |
| Oct 15, 2026 | 0.96 | 1.06 | 0.96 | 1.04 | 1.76M |
| Oct 14, 2026 | 1.00 | 1.02 | 0.96 | 0.99 | 3.00M |
| Oct 13, 2026 | 1.11 | 1.11 | 0.95 | 1.00 | 8.47M |
| Oct 12, 2026 | 1.16 | 1.18 | 1.09 | 1.11 | 2.33M |
| Oct 9, 2026 | 1.10 | 1.15 | 1.07 | 1.15 | 2.89M |
| Oct 8, 2026 | 1.17 | 1.18 | 1.08 | 1.09 | 3.21M |
| Oct 7, 2026 | 1.12 | 1.19 | 1.11 | 1.16 | 2.80M |
| Oct 6, 2026 | 1.15 | 1.17 | 1.12 | 1.13 | 2.01M |
| Oct 5, 2026 | 1.20 | 1.21 | 1.11 | 1.15 | 2.96M |
| Oct 2, 2026 | 1.22 | 1.23 | 1.16 | 1.16 | 2.91M |
| Oct 1, 2026 | 1.24 | 1.26 | 1.20 | 1.21 | 1.94M |
| Sep 30, 2026 | 1.14 | 1.24 | 1.13 | 1.22 | 2.68M |
| Sep 29, 2026 | 1.18 | 1.18 | 1.10 | 1.11 | 3.06M |
| Sep 28, 2026 | 1.18 | 1.21 | 1.14 | 1.17 | 1.90M |
| Sep 25, 2026 | 1.22 | 1.23 | 1.17 | 1.18 | 2.25M |
| Sep 24, 2026 | 1.26 | 1.26 | 1.18 | 1.21 | 2.85M |
| Sep 23, 2026 | 1.30 | 1.31 | 1.24 | 1.25 | 3.03M |
| Sep 22, 2026 | 1.25 | 1.34 | 1.25 | 1.29 | 2.93M |
| Sep 21, 2026 | 1.24 | 1.28 | 1.22 | 1.24 | 2.72M |
About Inovio Pharmaceuticals
Inovio Pharmaceuticals (INO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PLYMOUTH MEETING, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1055726.
INO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Simon X Benito | Director | May 21, 2026 |
| Roger D Dansey | Director | May 21, 2026 |
| Ann Calby Miller | Director | May 21, 2026 |
| Jacqueline Elizabeth Shea | Chief Executive Officer | May 21, 2026 |
| Jay Shepard | Director | May 21, 2026 |
| David B. Weiner | Director | May 21, 2026 |
| Wendy L Yarno | Director | May 21, 2026 |
| Lota S. Zoth | Director | May 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Laurent Humeau | Chief Scientific Officer | May 21, 2026 |
| Peter Kies | CFO | May 21, 2026 |
| Jacqueline Elizabeth Shea | Chief Executive Officer | May 21, 2026 |
| Michael John Sumner | Chief Medical Officer | May 21, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
INO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $65.34K | $-84.95M | -1.81 | $-88.63M |
| Dec 31, 2024 | $217.76K | $-107.25M | -3.95 | $-104.08M |
| Dec 31, 2023 | $832.01K | $-135.12M | -6.09 | $-124.37M |
| Dec 31, 2022 | $10.26M | $-279.82M | -14.07 | $-216.22M |
| Dec 31, 2021 | $1.77M | $-303.66M | -17.45 | $-215.71M |
Latest balance sheet: total assets $49.39M, total liabilities $45.02M, cash $31.53M (as of Jun 30, 2026).
INO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $0.77 |
| Jul 29, 2026 | 8-K Item 2.02 (results) | $1.04 |
| May 13, 2026 | 8-K Item 2.02 (results) | $1.34 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $1.68 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $2.15 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.49 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.92 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $2.10 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $4.77 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on INO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.